An update from Inoviq Ltd ( (AU:IIQ) ) is now available.
INOVIQ Ltd announced the publication of a scientific paper in the journal Breast Cancer Research and Treatment, highlighting the superior diagnostic performance of its neuCA15-3 test compared to the FDA-approved CA15-3 test for breast cancer monitoring. The neuCA15-3 test demonstrated an overall accuracy of 81% and showed potential for early-stage breast cancer detection when combined with other biomarkers. This milestone supports the test’s commercialization and partnering opportunities, with plans to further develop it for early detection and implement it on existing pathology instruments.
More about Inoviq Ltd
INOVIQ Ltd is a biotechnology company focused on pioneering next-generation diagnostics and therapeutics for cancer. The company has commercialized its EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test for bladder cancer. INOVIQ is advancing clinical-stage diagnostics for ovarian and breast cancers and early-stage exosome therapeutics for solid tumors.
YTD Price Performance: -21.36%
Average Trading Volume: 113,080
Technical Sentiment Signal: Buy
Current Market Cap: A$45.17M
See more data about IIQ stock on TipRanks’ Stock Analysis page.